As of today (2024-04-26), Exact Sciences's share price is $58.85.
Exact Sciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.17. Hence, Exact Sciences's Price-to-Free-Cash-Flow Ratio for today is 338.22.
The historical rank and industry rank for Exact Sciences's Price-to-Free-Cash-Flow or its related term are showing as below:
EXAS'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 150.88 Med: 329.33 Max: 420.69
Current: 338.19
During the past 13 years, Exact Sciences's highest Price-to-Free-Cash-Flow Ratio was 420.69. The lowest was 150.88. And the median was 329.33.
EXAS's Price-to-Free-Cash-Flow is ranked worse than 95.56% of 90
companies
in the Medical Diagnostics & Research industry
Industry Median: 27.885
vs EXAS: 338.19
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -27.90% per year.
During the past 13 years, Exact Sciences's highest 3-Year average Free Cash Flow per Share Growth Rate was 48.50% per year. The lowest was -30.60% per year. And the median was -1.80% per year.
Exact Sciences Price-to-Free-Cash-Flow Historical Data
The historical data trend for Exact Sciences's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Exact Sciences's Price-to-Free-Cash-Flow
For the Diagnostics & Research subindustry, Exact Sciences's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exact Sciences's Price-to-Free-Cash-Flow Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Exact Sciences's Price-to-Free-Cash-Flow falls into.
Exact Sciences's Share Price of today is $58.85. Exact Sciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.17.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Exact Sciences Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Exact Sciences's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Exact Sciences (Exact Sciences) Business Description
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EXAS has been successfully added to your 